您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > CDK1-IN-3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CDK1-IN-3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CDK1-IN-3图片
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
CDK1-IN-3 (8g) 是CDK1的选择性抑制剂,对 CDK1,CDK2 和 CDK5 的IC50值分别为 36.8,305.17 和 369.37 nM。CDK1-IN-3 通过影响细胞周期抑制癌细胞的生长。CDK1-IN-3 可用于癌症的研究。
生物活性

CDK1-IN-3 (8g) is a selectiveCDK1inhibitor withIC50s of 36.8, 305.17 and 369.37 nM forCDK1,CDK2andCDK5, respectively. CDK1-IN-3 inhibits the growth ofcancercells by affecting cell cycle. CDK1-IN-3 can be used for the research ofcancer[1].

IC50& Target

CDK1

36.8 nM (IC50)

CDK2

305.17 nM (IC50)

CDK5

369.37 nM (IC50)

体外研究
(In Vitro)

CDK1-IN-3 (0-10 μM; 24 h) inhibits the growth of PDAC, melanoma, leukemia, colon and breast cancer cells[1].
CDK1-IN-3 (0-1 μM) inhibits CDK1, CDK2 and CDK5 with IC50s of 36.8, 305.17 and 369.37 nM, respectively[1].
CDK1-IN-3 (0-10 μM) inhibits AXL, PTK2B, FGFR, JAK1, IGF1R and BRAF kinases with IC50s of 5655, 3632, 4626, 5265, 5514 and 2829 nM, respectively[1].
CDK1-IN-3 (0.51 μM; 24 h) decreases CDK1 protein level in virto and affects cell cycle[1].

Cell Proliferation Assay[1]

Cell Line:PDAC, melanoma, leukemia, colon and breast cancer cell lines
Concentration:0-10 μM
Incubation Time:24 hours
Result:Inhibited cell growth of PDAC, melanoma, leukemia, colon, and breast cancer cells over 61%, and inhibited MDA-PATC53 and PL45 cells with IC50s of 0.51 and 0.74 μM, respectively.

Western Blot Analysis[1]

Cell Line:MDA-PATC53 cell line
Concentration:0.51 μM
Incubation Time:24 hours
Result:Downregulated CDK1 protein level compared to untreated cells.

Western Blot Analysis[1]

Cell Line:MDA-PATC53 cell line
Concentration:0.51 μM
Incubation Time:24 hours
Result:Significantly arrested in G2/M phase of the cell cycle compared with the untreated cells.
分子量

555.98

Formula

C28H25ClF3N5O2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.